Jean‐François Patoiseau

Author

Also Known As

J F Patoiseau, J. F. PATOISEAU, J.-F Patoiseau, J.-F. Patoiseau, J.F. Patoiseau, J.‐F. PATOISEAU, JEAN‐FRANCOIS PATOISEAU, Jean-François Patoiseau, Jean‐Francois Patoiseau, Jean‐François Patoiseau

Publications

591

Citations

H-Index

Concepts

All Affiliations

Pierre Fabre (France)Pierre Fabre (Germany)

About

Jean‐François Patoiseau is an author at Pierre Fabre (France) specializing in medicine, pharmacology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	315
2	Biochemistry	2	2	47
3	Health Sciences	1	1	29
4	Natural Sciences	1	1	31
5	Allergy	1	1	231

Jean‐François Patoiseau

Publications

503

Citations

H-Index

Page 1

	Year	Citations
Immunological Quantitation and Localization of ACAT-1 and ACAT-2 in Human Liver and Small Intestine Catherine C.Y. Chang, Naomi Sakashita, Kim Ørnvold, Journal of Biological Chemistry Laboratory ImmunologyImmunologyGastroenterologyPathologyImmunotherapy	2000	231
F 11440, a Potent, Selective, High Efficacy 5-HT1AReceptor Agonist with Marked Anxiolytic and Antidepressant Potential Wouter Koek, Jean‐François Patoiseau, M.B. Assié, Journal of Pharmacology and Experimental Therapeutics	1998	63
Human Adipocyte Fatty Acid-Binding Protein (aP2) Gene Promoter-Driven Reporter Assay Discriminates Nonlipogenic Peroxisome Proliferator-Activated Receptor γ Ligands Yves Rival, Aline Stennevin, L. Puech, Journal of Pharmacology and Experimental Therapeutics	2004	53
Pharmacological profile of F 12511, (S)-2′,3′,5′-trimethyl-4′-hydroxy-α-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor Didier Junquéro, Philippe Oms, Elisabeth Carilla-Durand, Biochemical Pharmacology Molecular PharmacologyMedicinal ChemistryPharmaceutical ScienceSystemic AcylcoenzymeOxysterol	2001	31
F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet Didier Junquéro, F. Bruniquel, Xuân Hồng Nguyễn, Atherosclerosis NutritionMetabolic SyndromeCardiovascular DiseaseMedicineF 12511	2001	29
Investigation of the Mechanism by which Ketanserin Prolongs the Duration of the Cardiac Action Potential Bruno Le Grand, Jean‐Michel Talmant, Jean-Pierre Rieu, Journal of Cardiovascular Pharmacology	1995	27
Cardiovascular Drugs Inhibit MMP-9 Activity from Human THP-1 Macrophages Yves Rival, Nathalie Benéteau, Violaine Chapuis, DNA and Cell Biology InflammationVascular DiseaseAtherosclerosis ComplicationsCardiovascular DiseaseMedicine	2004	24
Lack of toxic effects of F 12511, a novel potent inhibitor of acyl-coenzyme A: cholesterol O-acyltransferase, on human adrenocortical cells in culture11Abbreviations: ACAT, acyl-coenzyme A: cholesterol O-acyltransferase; F 12511, (S)-2′,3′,5′-trimethyl-4′-hydroxy-α-dodecylthio-phenylacetanilide; DMEM, Dulbecco’s modified Eagle medium; FBS, fetal bovine serum; LDL, low-density lipoprotein; HDL, high-density lipoprotein; SR-BI, scavenger receptor class B, type I; P450scc, cytochrome P450 cholesterol side-chain cleavage; P450c17, cytochrome P450 17 α-hydroxylase; P450c21, cytochrome P450 21-hydroxylase; PMA, phorbol 12-myristate 13-acetate; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; cAMP, adenosine 3′5′-cyclic monophosphate; ITS, insulin-transferrin-linoleic acid; and MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide. Didier Junquéro, Antoine Pilon, Elizabeth Carilla-Durand, Biochemical Pharmacology	2001	19
Characterization of Polymorphs and Solvates of 3-Amino-1-(m-trifluoromethylphenyl)-6-methyl-1H-pyridazin-4-one Alain Chauvet, Jacqueline Masse, Jean‐Paul Ribet, Journal of Pharmaceutical Sciences Organic ChemistryHeterocycle ChemistryFluorous SynthesisBiochemistry	1992	16
[Crystalline polymorphism of eflucimibe]. J. P. Ribet, R. Pena, Alexandre Chauvet, PubMed	2002	10

Page 1